Latest Headlines
Age should not affect chemotherapy choice for stage IV lung cancer: guidelines
Early PET-CT predicts treatment response of head and neck cancer
Evidence scarce to support RF ablation of colorectal CA metastases in the liver
Casopitant helps curb chemotherapy emesis
Australian scientists plan to regrow breasts after cancer
NEWS PROVIDED BY 
VIEW ALL NEWSProstate cancer anxiety may affect therapy choices
NEW YORK (Reuters Health) - Among men who have been treated for prostate cancer, those who are particularly anxious after signs of a recurrence may not make the best decision about the next step in treatment, new research shows.
Specifically, older prostate cancer patients who have a high level of anxiety when their PSA levels starts rising are likely to opt quickly for androgen deprivation therapy (ADT) before it's necessary.
This finding is important since early ADT -- which aims to eliminate testosterone that drives cancer growth -- may not improve survival but could have a negative effect on quality of life, Dr. William Dale, from the University of Chicago, and colleagues point out in the Journal of Clinical Oncology.
The researchers assessed the emotional state of 67 men with a recurrence of prostate cancer indicated by a rising PSA level. A third of the men decided to start ADT quickly.
A high score on a scale measuring anxiety related to prostate cancer meant that a patient was 9 times more likely than someone with a lower score to choose early treatment.
The findings suggest that "the non-clinical factor of patient anxiety about cancer may be both important and overlooked in choosing when to initiate ADT," Dale and colleagues conclude.
It is important for patients and their doctors to discuss worries and anxieties about cancer, they add. "Doing so may help prevent unnecessary early initiation of a therapy with significant toxicities and questionable impact on life expectancy in otherwise asymptomatic older men."
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 